Alumis Appoints Sapna Srivastava, Ph.D., to its Board of Directors
SOUTH SAN FRANCISCO, Calif. – Alumis, a precision immunology company incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the appointment of Sapna Srivastava, Ph.D., a biotechnology and financial industry leader, to its board of directors.
“We are pleased to welcome Sapna to our board, whose demonstrated track record of leading successful business strategy and financial organizations across the biotechnology industry will be highly valuable to Alumis,” said Martin Babler, president and chief executive officer of Alumis. “Sapna’s industry experience, combined with her time spent on Wall Street, offers a unique perspective, and we look forward to partnering with her as we continue to advance our precision immunology programs.”
“Through the combination of its precision analytics platform and a team with deep experience in immunology and successful drug development, Alumis has an opportunity to rewrite the way autoimmune diseases are treated,” said Dr. Srivastava. “I look forward to collaborating with the board and management team to advance the business and precision immunology pipeline.”
Dr. Srivastava is an experienced senior executive within the biopharmaceutical industry and Wall Street. Previously, Dr. Srivastava was the chief financial and strategy officer for Abide Therapeutics (acquired by Lundbeck), and prior to that, was chief financial and strategy officer for Intellia Therapeutics. She played an integral role in helping build Intellia’s financial operations and strategic direction, as well as the company’s Series B financing and its initial public offering. Prior to her industry experience, she spent nearly 15 years as a stock analyst for the biotechnology sector on Wall Street, including as the senior analyst and team leader of the biotechnology group at Goldman Sachs; a senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners; and as a research associate at JP Morgan. Dr. Srivastava also has experience as an independent board member for several therapeutic focused biotechnology companies and nonprofits. Dr. Srivastava holds a Ph.D. from New York University School of Medicine and a B.Sc. from St. Xavier’s College, University of Bombay.
Alumis is a precision immunology company looking to eliminate the “all comer” approach that is seen with today’s treatments for people with autoimmune disease. Even with innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Alumis leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug discovery, development and immunology, in order to create medicines that change the lives of people with autoimmune disease. For more information, please visit alumis.com.
Dan Budwick, 1AB